{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:21:41Z","timestamp":1784276501192,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The Janus kinase (JAK) inhibitor baricitinib may block viral entry into pneumocytes and prevent cytokine storm in patients with SARS-CoV-2 pneumonia. We aimed to assess whether baricitinib improved pulmonary function in patients treated with high-dose corticosteroids for moderate to severe SARS-CoV-2 pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational study enrolled patients with moderate to severe SARS-CoV-2 pneumonia [arterial oxygen partial pressure (PaO2)\/fraction of inspired oxygen (FiO2) &amp;lt;200\u2009mmHg] who received lopinavir\/ritonavir and HCQ plus either corticosteroids (CS group, n\u2009=\u200950) or corticosteroids and baricitinib (BCT-CS group, n\u2009=\u200962). The primary end point was the change in oxygen saturation as measured by pulse oximetry (SpO2)\/FiO2 from hospitalization to discharge. Secondary end points included the proportion of patients requiring supplemental oxygen at discharge and 1\u2009month later. Statistics were adjusted by the inverse propensity score weighting (IPSW).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A greater improvement in SpO2\/FiO2 from hospitalization to discharge was observed in the BCT-CS vs CS group (mean differences adjusted for IPSW, 49; 95% CI: 22, 77; P\u2009&amp;lt;\u20090.001). A higher proportion of patients required supplemental oxygen both at discharge (62.0% vs 25.8%; reduction of the risk by 82%, OR adjusted for IPSW, 0.18; 95% CI: 0.08, 0.43; P &amp;lt; 0.001) and 1\u2009month later (28.0% vs 12.9%, reduction of the risk by 69%, OR adjusted for IPSW, 0.31; 95% CI: 0.11, 0.86; P\u2009=\u20090.024) in the CS vs BCT-CS group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>. In patients with moderate to severe SARS-CoV-2 pneumonia a combination of baricitinib with corticosteroids was associated with greater improvement in pulmonary function when compared with corticosteroids alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, ENCEPP (EUPAS34966, http:\/\/www.encepp.eu\/encepp\/viewResource.htm? id = 34967)<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa587","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T03:51:48Z","timestamp":1597809108000},"page":"399-407","source":"Crossref","is-referenced-by-count":103,"title":["Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study"],"prefix":"10.1093","volume":"60","author":[{"given":"Jose Luis","family":"Rodriguez-Garcia","sequence":"first","affiliation":[{"name":"Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3910-2955","authenticated-orcid":false,"given":"Gines","family":"Sanchez-Nievas","sequence":"additional","affiliation":[{"name":"Rheumatology, General University Hospital of Albacete, Albacete"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Arevalo-Serrano","sequence":"additional","affiliation":[{"name":"Internal Medicine, Principe de Asturias University Hospital, Alcala de Henares"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Garcia-Gomez","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Jimenez-Vizuete","sequence":"additional","affiliation":[{"name":"Anaesthesiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Martinez-Alfaro","sequence":"additional","affiliation":[{"name":"Infectious Diseases, General University Hospital of Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"2021010517015573300_keaa587-B1","doi-asserted-by":"crossref","first-page":"2001028","DOI":"10.1183\/13993003.01028-2020","article-title":"Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers","volume":"55","author":"Rello","year":"2020","journal-title":"Eur Respir J"},{"key":"2021010517015573300_keaa587-B2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"2021010517015573300_keaa587-B3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa601","article-title":"Early short course corticosteroids in hospitalized patients with COVID-19","author":"Fadel","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021010517015573300_keaa587-B4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"2021010517015573300_keaa587-B5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/keaa194","article-title":"COVID-19: an unexpected indication for anti-rheumatic therapies?","volume":"59","author":"Lucchino","year":"2020","journal-title":"Rheumatology"},{"key":"2021010517015573300_keaa587-B6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021010517015573300_keaa587-B7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021010517015573300_keaa587-B8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1538-7836.2007.02313.x","article-title":"The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview","volume":"5","author":"Toh","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2021010517015573300_keaa587-B9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/2589645801812010026","article-title":"Clinical early warning scores: new clinical tools in evolution","volume":"12","author":"Doyle","year":"2018","journal-title":"Open Anesthesia J"},{"key":"2021010517015573300_keaa587-B10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1378\/chest.07-0617","article-title":"Comparison of the SpO2\/FIO2 ratio and the PaO2\/FIO2 ratio in patients with acute lung injury or ARDS","volume":"132","author":"Rice","year":"2007","journal-title":"Chest"},{"key":"2021010517015573300_keaa587-B11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Elm","year":"2007","journal-title":"Lancet"},{"key":"2021010517015573300_keaa587-B12","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2021010517015573300_keaa587-B13","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"2021010517015573300_keaa587-B14","doi-asserted-by":"crossref","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2021010517015573300_keaa587-B15","first-page":"64","article-title":"Activation of coagulation and fibrinolysis in acute respiratory distress syndrome: a prospective pilot study","volume":"3","author":"Ozolina","year":"2016","journal-title":"Front Med (Lausanne)"},{"key":"2021010517015573300_keaa587-B16","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jth.14859","article-title":"D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19","volume":"18","author":"Zhang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021010517015573300_keaa587-B17","first-page":"167","article-title":"COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)","volume":"18","author":"Marietta","year":"2020","journal-title":"Blood Transfus"},{"key":"2021010517015573300_keaa587-B18","first-page":"694","article-title":"The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib","volume":"37","author":"Choy","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2021010517015573300_keaa587-B19","first-page":"430","article-title":"Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients with rheumatoid arthritis","volume":"21","author":"van den","year":"1994","journal-title":"J Rheumatol"},{"key":"2021010517015573300_keaa587-B20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"2021010517015573300_keaa587-B21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with middle east respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010517015573300_keaa587-B22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/cid\/ciaa351","article-title":"Factors associated with prolonged viral RNA shedding in patients with COVID-19","volume":"71","author":"Xu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021010517015573300_keaa587-B23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet"},{"key":"2021010517015573300_keaa587-B24","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jinf.2020.03.062","article-title":"The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis","volume":"81","author":"Yang","year":"2020","journal-title":"J Infect"},{"key":"2021010517015573300_keaa587-B25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2021010517015573300_keaa587-B26","doi-asserted-by":"crossref","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2021010517015573300_keaa587-B27","first-page":"37","article-title":"Baricitinib: a 2018 novel FDA-approved small. Molecule inhibiting janus kinases","volume":"12","author":"Mayence","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2021010517015573300_keaa587-B28","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J Clin Invest"},{"key":"2021010517015573300_keaa587-B29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021010517015573300_keaa587-B30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann Pharmacother"},{"key":"2021010517015573300_keaa587-B31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"2021010517015573300_keaa587-B32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"2021010517015573300_keaa587-B33","doi-asserted-by":"crossref","DOI":"10.1101\/2020.05.24.20111971","article-title":"Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMICOVID-19 Network","volume-title":"MedRxiv","author":"Casas","year":"2020"},{"key":"2021010517015573300_keaa587-B34","doi-asserted-by":"crossref","article-title":"Dexamethasone in hospitalized patients with Covid-19 - Preliminary report","author":"Horby","DOI":"10.1101\/2020.06.22.20137273"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/399\/35433414\/keaa587.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/399\/35433414\/keaa587.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T15:29:57Z","timestamp":1667921397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/1\/399\/5918130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,6]]},"published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa587","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,10,6]]}}}